Flere og flere studier viser til Calprotectin sin rolle i diagnostikk og monitorering av sykdommer, hjertehelse, covid, sepsis og til og med kreft (Gastric Cancer). Når skal dette reflekteres i flere partneravtaler og økende salg?
S100a8/A9 proteins: critical regulators of inflammation in cardiovascular diseases
Increasingly, research suggests that the concentrations of S100A8/A9 proteins in the bloodstream could be pivotal prognostic markers for negative cardiovascular outcomes in patients with acute and chronic heart failure, myocarditis, and thrombosis. Despite the intricate regulatory mechanisms of S100A8/A9, which involve complex transcriptional and post-translational processes and result in varied biological functions, the progress in developing potential therapeutics, such as humanized vaccines, antibodies, and inhibitors against S100A8/A9, is encouraging. These experimental findings have been successfully adapted to establish safe dosages for various immunoinflammatory diseases in clinical practice. Looking ahead, with the advancement of research technologies, the S100A8/A9 protein is expected to become a new focus for the diagnosis and treatment of cardiovascular diseases, potentially revolutionizing clinical approaches to diagnosis and therapy.
# The role of the S100A8/S100A9 in gastric tumor progression
In conclusion, our study identified a subtype of S100A8 and S100A9-positive macrophages that significantly increased in the EGC. Our results suggest that S100A8 and S100A9 may be potential markers for the diagnosis and risk assessment of GC, and they can promote gastric cancer cell proliferation and migration through the S100A8/S100A9- NFκB signaling pathway, ultimately leading to gastric tumor progression.
Conclusions
In this cohort, one third of the children that were prescribed antibiotics did not have confirmed bacterial infection. Hence, there is a need for adequate diagnostic tools to help discriminate between various kinds of infections. This study confirms serum calprotectin as a valuable biomarker for differentiation between types of infection and estimation of disease severity in febrile infants. Access to fast and accurate analysis of circulating calprotectin, combined with good clinical performance has the potential to make this biomarker a valuable complement to the current diagnostics of patients with bacterial infections and sepsis.
Calprotectin serum levels were elevated in patients with moderate COVID-19 compared with controls, and these levels were further increased in the severe cases. Patients with severe COVID-19 and vancomycin-resistant enterococci (VRE) bacteremia had elevated calprotectin levels, but their C-reactive protein and procalcitonin levels were not increased. Fungal superinfections and herpes simplex virus reactivation did not change the calprotectin levels. A calprotectin concentration of 31.29 µg/mL can be used to diagnose VRE bloodstream infection with 60% sensitivity and 96% specificity. These data suggest that serum calprotectin may be a promising biomarker for the early detection of VRE bloodstream infections in patients with COVID-19.
# Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis
Conclusions
Serum calprotectin and zonulin levels emerge as noninvasive prognostic biomarkers for potentially unfavorable outcomes in patients with decompensated cirrhosis.
